Eyam Vaccines and Immunotherapeutics

🌟 Exciting News from Eyam Vaccines and Immunotherapeutics! 🌟 We’re proud to announce that Professor Janet Hemingway, a world-renowned leader in tropical medicine and vector-borne diseases, has joined Eyam’s Board of Advisors. 🎉 Professor Hemingway’s extraordinary career spans over four decades, during which she has built transformative organizations and made groundbreaking contributions to global public health. As the former Director of the Liverpool School of Tropical Medicine (LSTM) and Founding Director of the iiCON: Infection Innovation Consortium, she not only advanced cutting-edge research but also established highly successful institutions that have left a lasting global impact. At iiCON, she built a portfolio valued at £222.3 million, connected over 1,000 organizations, and created 770 jobs—all in just four years. Her proven track record in scaling impactful initiatives positions her as an invaluable advisor as Eyam accelerates its growth trajectory. Our CEO, Ryan M. Thomas, shared: “Professor Hemingway’s success in building globally recognized biotechs and institutes makes her an unparalleled asset to Eyam. Her guidance on the business-building side will be instrumental as we scale our operations and forge partnerships that will redefine global health solutions.” Professor Hemingway expressed her enthusiasm: “I am honored to join Eyam at such an exciting time in the company’s growth. Eyam’s innovative approaches represent the next frontier in global health solutions, and I look forward to contributing to their mission.” This marks another significant milestone for Eyam as we continue to accelerate our research, forge meaningful collaborations, and expand our global impact. Together, we are one step closer to reshaping the future of healthcare. 💡 Let’s make history, together! #EyamVaccines #InnovationInHealth #GlobalHealth #Leadership #Biotech

What an Incredible Week at Eyam! Following our post earlier this week, we’re proud to share that Eyam Vaccines and Immunotherapeutics has now announced a third new strategic partnership just in the last six weeks—a significant milestone as we expand our footprint in both human and animal health. This exciting progress highlights Eyam’s ability to deliver advanced, scalable solutions across high-demand markets. Our recent collaborations showcase the growing trust in Eyam’s platforms, from human therapeutics to the rapidly expanding $75 billion animal health sector. Each partnership strengthens our mission to address global health challenges with precision and efficacy, driving real impact across industries. As Ryan M. Thomas, CEO, put it: “These partnerships reinforce Eyam’s vision to push biotech innovation forward across multiple sectors. We’re moving at an accelerated pace, seizing opportunities that allow Eyam to make an impact across species and regions.” Thank you to our dedicated team, our investors, and each new partner for believing in Eyam’s mission.  We’re just getting started, and there’s so much more to come! Catch up on our recent announcements below, and stay tuned for what’s next! https://lnkd.in/g4JY-F-U #Biotechnology #AnimalHealth #HumanHealth #Innovation #GlobalHealth #Eyam #Partnerships

🚀 Exciting News from Eyam Vaccines and Immunotherapeutics! 🚀 We’re thrilled to announce a strategic partnership with a global leader in animal health, marking an important expansion of Eyam’s commercial opportunities. Beyond our transformative work in human vaccines and therapeutics, Eyam is now entering the fast-growing animal health sector, a $75 billion market projected for 2025. This collaboration strengthens our vision to provide advanced solutions across infectious diseases, chronic diseases, cancer, and animal health. Our proprietary platforms, designed for more effective vaccine and therapeutic delivery, are now set to address critical needs in animal health—enhancing disease prevention and treatment options with unparalleled precision and efficacy. Ryan M. Thomas, CEO, emphasized: “This partnership is a testament to Eyam’s commitment to scaling our groundbreaking technologies into new, high-demand areas like animal health. By collaborating with a leader in this space, we’re unlocking significant commercial potential across industries.” As Eyam broadens its impact and reaches new industries, we’re committed to tackling global health challenges and improving lives across species. This partnership exemplifies our dedication to advancing next-generation biotech solutions that make a difference. 🌍💉🐾 👉 Learn more: https://lnkd.in/gZZSHB7U #Biotechnology #AnimalHealth #Vaccines #Therapeutics #Partnerships #GlobalHealth #Eyam

🌱 Innovating Animal Health with Eyam’s Groundbreaking Technologies 🐾 This month, Eyam is shining a spotlight on an essential and often under-discussed sector: the Animal Health Industry. Why focus on animal health now? 🔑 Food Security: Healthy livestock means stable food systems. Eyam’s innovations help prevent diseases that could disrupt food production, ensuring a resilient global food chain. 🌍 Zoonotic Disease Prevention: Diseases like SARS, MERS, and COVID-19 originated in animals. By advancing vaccines and therapies for animals, Eyam is playing a vital role in safeguarding public health. 💼 Business Opportunities: The animal health sector is expanding, with strong demand for vaccines and treatments. Eyam’s low-cost, scalable DNA vaccines are opening new avenues for partnerships and growth. Our DNA vaccine technology offers exceptional benefits: • Cost-Efficiency: Production costs may be as low as pennies per dose, making mass vaccination more affordable. • Stability: Our vaccines remain effective under various conditions, reducing distribution challenges. • Durability: Longer-lasting immune responses mean fewer interventions and better animal welfare. Eyam’s entry into the animal health market promises to revolutionize how vaccines are produced, stored, and administered, benefiting farmers, veterinarians, and animals alike. As we continue to push boundaries in biotech, Eyam’s advanced platforms are poised to make a transformative impact on global food security, zoonotic disease prevention, and animal care. 🚜💉 #AnimalHealth #BiotechInnovation #FoodSecurity #ZoonoticDiseases #EyamVaccines #Sustainability #VeterinaryScience https://lnkd.in/ggBMwcQb

We're #hiring a new Sales Representative in United States. Apply today or share this post with your network.

🌍 Mpox is on the rise again, with the WHO reporting a troubling resurgence. At Eyam, we are responding swiftly to this global health challenge. Our AI-driven Jennerator platform and Gemini DNA/RNA self-amplifying vaccines are designed to rapidly address such outbreaks with more efficacy and lower doses. We’re leveraging innovative technologies to develop vaccines that are stable, accessible, and easy to distribute, without the need for traditional cold storage. Our approach ensures that vaccines can reach the most vulnerable populations across the globe. 🔍 In our latest blog post, we dive into the latest updates on the Mpox outbreak and Eyam's cutting-edge response to combat it. Let’s take action together to prevent future pandemics! 💡 Read more here: https://lnkd.in/gum5wzv9 #Mpox #VaccineInnovation #GlobalHealth #Biotech #PandemicPreparedness #AI

⭐ Exciting News from Eyam Vaccines and Immunotherapeutics! ⭐ We are happy to announce that Eyam has been awarded a grant from the Bill & Melinda Gates Foundation! 🎉This funding will accelerate the development of our cutting-edge Gemini Expression Platform, an innovative technology that has the potential to transform the delivery of therapeutic proteins. Our CEO, Ryan M. Thomas, emphasized, “This grant is a key milestone for the Gemini platform, unlocking new opportunities to create long-lasting, low-cost treatments across various diseases.” 🌍 ✨ Dr. Wilfred Jefferies, Founder and Chief Scientific Officer at Eyam, added,  “The Gemini Platform represents a significant advance in therapeutic delivery. Its novel approach to achieving consistent, long-term protein expression could redefine how we develop and administer protein-based therapies.” This project will propel our research forward, delivering durable protein-based treatments that have the potential to greatly improve patient outcomes and transform the future of healthcare globally. 🔬 Read the full press release here: https://lnkd.in/gdXMW_7u Stay tuned as we embark on this journey to tackle some of the world’s most pressing health challenges! #HealthcareInnovation #Biotech #ProteinTherapeutics #GlobalHealth #GatesFoundation #EyamVaccines #TransformingHealthcare

🌟 August Insights from Eyam: Embracing AI and Navigating the Biotech Landscape 🌟 As August kicks off, we’re reminded of the unique opportunities in biotech. With interest rates falling and technological innovation accelerating, the stage is set for significant advancements in our field. In our latest newsletter, we dive deep into the integration of AI in drug design, addressing the hype versus reality. At Eyam, we’re not just adopting AI for the sake of it; we’re strategically integrating it into our Jennerator platform to enhance vector awareness and ensure that our therapies are not only potent but effectively delivered. 🔍Key Highlights: 1. The importance of vector awareness in drug delivery. 2. How AI-driven platforms like Jennerator are revolutionizing vaccine and therapeutic design. 3. Ethical considerations in the use of AI in biotech. We believe that by addressing these challenges head-on, Eyam is positioned to lead in the development of safer, more effective treatments that are accessible globally. Join the conversation and share your thoughts on AI’s role in drug design. Let’s push the boundaries of science together! 🔗https://lnkd.in/e-R4B9jQ Ryan M. Thomas #AIinBiotech #Innovation #DrugDesign #Biotechnology #Eyam #Pharma #AI #VaccineDevelopment #EthicalAI #LifeSciences

Eyam Vaccines and Immunotherapeutics In case you missed it, Eyam Vaccines and Immunotherapeutics announced last week the appointment of Nicholas Franco to its Board of Advisors. Mr. Franco has held key executive level leadership positions in several prominent organizations, including his most recent role as Executive Vice President and Chief Business Development Officer at Actelion, a Janssen Pharmaceutical Company of Johnson & Johnson. His expertise in business development, commercialization and leading organizations has significantly contributed to the growth and innovation in the companies he has served. Ryan M. Thomas, Chief Executive Officer of Eyam, expressed his enthusiasm about Franco joining the advisory board. “Eyam is excited to welcome Nicholas as a member of our Advisory Board. His skills, experience and contacts in business development will immediately translate into new opportunities for Eyam’s technologies.” https://lnkd.in/gi5kY4bP

Recent findings by the WHO reveal the detection of the H5N1 bird flu virus in raw milk, raising concerns about its implications for food safety and public health. This marks an impactful discovery, as transmission routes of the virus now appear to include not just birds but also cows, and potentially, milk. While pasteurization ensures the safety of commercial milk, these developments highlight the need for vigilant food safety practices. Read more about the ongoing investigations and the global response here: https://lnkd.in/gV4iXHW9 #PublicHealth #FoodSafety #H5N1 #WHO